P. Kent Hawryluk - 12 Sep 2024 Form 3 Insider Report for MBX Biosciences, Inc. (MBX)

Role
President & CEO, Director
Signature
/s/ Richard Bartram, attorney-in-fact
Issuer symbol
MBX
Transactions as of
12 Sep 2024
Net transactions value
$0
Form type
3
Filing time
12 Sep 2024, 19:34:05 UTC
Next filing
17 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MBX Common Stock 197,551 12 Sep 2024 Direct
holding MBX Common Stock 282,363 12 Sep 2024 By Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MBX Stock Option (right to buy) 12 Sep 2024 Common Stock 312,567 $3.25 Direct F2
holding MBX Stock Option (right to buy) 12 Sep 2024 Common Stock 718,391 $7.82 Direct F3
holding MBX Series A Convertible Preferred Stock 12 Sep 2024 Common Stock 167,664 Direct F4
holding MBX Series A Convertible Preferred Stock 12 Sep 2024 Common Stock 28,755 By Trust F1, F4
holding MBX Series B Convertible Preferred Stock 12 Sep 2024 Common Stock 116,182 Direct F4
holding MBX Series B Convertible Preferred Stock 12 Sep 2024 Common Stock 6,402 By Trust F1, F4
holding MBX Series C Convertible Preferred Stock 12 Sep 2024 Common Stock 80,757 By Trust F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
F2 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of November 7, 2022, subject to the Reporting Person's continued service on each such vesting date.
F3 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 15, 2023, subject to the Reporting Person's continued service on each such vesting date.
F4 Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and will automatically convert into the number of shares shown in Column 3 immediately prior to the closing of the Issuer's initial public offering. The Preferred Stock has no expiration date.

Remarks:

Exhibit 24 - Power of Attorney